Prepping for Trump

The new political reality in Washington presents opportunities, threats and a lot of food for thought for leaders of industries like biopharma that need effective public policy to thrive.

The opportunities are real. Drugmakers are likely to persuade Congress to modify the Inflation Reduction Act’s Medicare drug price negotiation program, and to benefit from the appointment of an FTC commissioner who will adopt a traditional approach to antitrust enforcement. ...